Plaque Psoriasis
340
27
47
234
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
137 trials with published results (40%)
Research Maturity
234 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.6%
19 terminated out of 340 trials
92.5%
+6.0% vs benchmark
45%
154 trials in Phase 3/4
59%
137 of 234 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 234 completed trials
Clinical Trials (340)
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Modifying PEST for Psoriatic Arthritis Screening
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bimekizumab in Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis